Close
ACHEMA MIDDLE EAST 2026

Bayer, NextRNA Ink $547Million Deal For Cancer Therapies

This summer, Bayer officials made sure Fierce understood that the company's desire for deals hasn't been stifled by a group-wide reorganization. Its most recent...

New Endometrial Cancer Care Phase II Results Encouraging

The most recent trial of a new antibody drug that goes on to deliver potent chemotherapy that too directly to the cancer cells for...

Duality Keeps An Eye Out For Hong Kong IPO For ADC Trials

Duality Biotherapeutics from China has gone ahead and filed paperwork as far as a Hong Kong IPO is concerned, thereby looking out for an...

Siemens Healthineers, Novartis Partner To Grow PET Imaging

In a recent development taking place in the last week of August 2024, Siemens Healthineers has gone ahead and agreed to pay over 200...

Steady Growth Forecasted For Global Pharma Packaging Market

Over the course of the next ten years, the global market for pharmaceutical grade plastic packaging is expected to see consistent growth. Over the next...

Cold Chain Optimization For Safe Pharmaceutical Delivery

Supply chain optimization for the safety of pharmaceuticals As summertime temperatures increase, it becomes more crucial to ensure the safety of pharmaceutical items. Elevated temperatures...

Effectiveness of Industrial Refrigeration In Pharma Spectrum

Industrial refrigeration happens to play a pivotal role in the pharma sector, in which the precise control is necessary in terms of maintaining safety,...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...